Augmenting a paralyzed vocal fold to close the glottic gap and restore voice
Unilateral vocal fold paralysis (UVFP) results from injury to the recurrent laryngeal nerve (RLN) or, less commonly, the vagus nerve itself. The paralyzed fold settles in a fixed paramedian position while the contralateral fold retains full mobility. During phonation the mobile fold cannot fully compensate, leaving a persistent glottic gap — glottic insufficiency — that causes a breathy, weak voice and, in more severe cases, aspiration of liquids.
The recurrent laryngeal nerve is a branch of the vagus (cranial nerve X) that supplies every intrinsic laryngeal muscle except the cricothyroid, which is innervated by the external branch of the superior laryngeal nerve. On the right, the RLN loops beneath the subclavian artery before ascending in the tracheoesophageal groove; on the left it travels much further, looping under the arch of the aorta. This longer, more exposed left-sided course is why left vocal fold paralysis is roughly two to four times more common than right.
The most frequent causes of RLN injury are iatrogenic — thyroidectomy and parathyroidectomy account for roughly a third of cases, followed by other cervical and cardiothoracic procedures (anterior cervical spine surgery, esophagectomy, cardiac and aortic arch surgery, lung apex resection) where the nerve runs in harm’s way. Malignancy — thyroid, lung apex (Pancoast tumor), esophageal, or mediastinal cancers compressing or invading the nerve — must always be excluded, particularly for left-sided paralysis given the nerve’s mediastinal course. When no cause is found after full workup, the paralysis is labeled idiopathic and is presumed viral or inflammatory in origin in many cases.
Because the left RLN loops around the aortic arch deep in the mediastinum, left-sided UVFP carries a higher index of suspicion for thoracic malignancy and should prompt cross-sectional imaging from the skull base to the aortic arch if no surgical cause is evident.
When the RLN is injured, all intrinsic adductors and the sole abductor (posterior cricoarytenoid) lose their nerve supply, but the cricothyroid muscle — innervated separately by the superior laryngeal nerve — remains active. The unopposed tonic pull of the cricothyroid tilts the thyroid cartilage and tenses the paralyzed fold, drawing it toward a paramedian resting position rather than fully abducted (the classic Wagner-Grossman explanation).
This paramedian position is clinically fortunate: it places the paralyzed fold close enough to the midline that the mobile fold often achieves partial — but rarely complete — glottic closure on its own. The residual defect is usually a posterior, spindle- or teardrop-shaped gap centered near the vocal processes of the arytenoid cartilages, since the anterior commissure (where both folds are tethered to the thyroid cartilage) stays essentially apposed.
Patients typically present with a breathy, weak, and easily fatigued voice, reduced maximum phonation time, vocal effort, and — importantly — aspiration of thin liquids, since a partially open glottis cannot protect the airway during the pharyngeal swallow. Diagnosis is made with flexible fiberoptic laryngoscopy or videostroboscopy, observing fold mobility during quiet breathing, phonation, and cough.
The glottic gap is estimated visually or with calibrated software during phonation; gaps exceeding roughly 2 mm correlate with a measurably increased risk of laryngeal penetration and aspiration on videofluoroscopic swallow study. Laryngeal electromyography can help distinguish paralysis from cricoarytenoid joint fixation and offers prognostic information about the likelihood of spontaneous reinnervation, which — when it occurs — usually happens within 6 to 12 months of nerve injury.
Once glottic insufficiency is confirmed, the clinician chooses between temporary, resorbable fillers and permanent framework surgery. Injection laryngoplasty — bulking the paralyzed fold with an injectable material to push it medially — is the workhorse first-line treatment, valued for its quick in-office delivery, low morbidity, and its usefulness as a diagnostic trial before committing to permanent surgery.
The paraglottic space is a potential fibrofatty compartment bounded medially by the conus elasticus and quadrangular membrane, laterally by the thyroid cartilage lamina and thyrohyoid membrane, and containing the thyroarytenoid (vocalis) muscle. It is continuous from the level of the true vocal fold up into the false fold and forms the natural target plane for augmentation: filler placed here bulks the fold’s lateral bulk without needing to touch the delicate vibratory mucosa of the free edge.
Accurate placement — typically at or just lateral to the mid-membranous fold and vocal process — pushes the fold’s free margin medially so that it meets the mobile fold at the midline during phonation, while preserving the mucosal wave needed for normal voice quality.
No single filler is ideal for every patient. The choice balances expected duration of RLN recovery, desired permanence, reversibility, and the clinical setting (in-office awake vs. operating room under general anesthesia). Hyaluronic acid is popular for its short-term reliability and reversibility (it can be dissolved with hyaluronidase if overcorrected), making it a good "trial" material while awaiting possible spontaneous reinnervation. Calcium hydroxylapatite and autologous fat are chosen when a longer-lasting or more permanent result is desired.
Because 6–12 months is the usual window for spontaneous RLN recovery, a short- to medium-acting filler such as hyaluronic acid is generally preferred for early or presumed-recoverable paralysis, reserving longer-acting materials or permanent thyroplasty for paralysis confirmed to be chronic.
Injection laryngoplasty is favored when: the paralysis is recent and reinnervation is still possible; the patient is a poor candidate for an operating-room procedure; aspiration needs urgent correction (e.g., in a frail or post-surgical patient); or as a diagnostic trial to predict the benefit of a permanent procedure.
Type I medialization thyroplasty (a Silastic or Gore-Tex implant placed through a thyroid cartilage window) and arytenoid adduction are considered once paralysis is confirmed permanent — typically after 9 to 12 months without recovery — or when repeated injections become impractical. Many patients who respond well to a temporary filler go on to have durable, comparable benefit from framework surgery, so injection often serves as both treatment and predictive test.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Hyaluronic acid (HA) | Restylane, Juvéderm Voice, Hylaform | Biocompatible polysaccharide gel; reversible with hyaluronidase | 3–6 mo duration — ideal trial filler while awaiting recovery |
| Calcium hydroxylapatite (CaHA) | Radiesse Voice, Radiesse Voice Gel | Microspheres in a carrier gel; stimulates modest local collagen | 12–18 mo duration — semi-permanent, fewer repeat visits |
| Autologous fat | Harvested from abdomen/thigh | Autologous adipocytes placed under general anesthesia | Potentially years-long if it "takes"; no foreign material |
| Carboxymethylcellulose / micronized dermis | Short-acting temporizing agents | Resorbable gel or processed dermal matrix | Weeks to a few months — very short diagnostic trial |
Injection laryngoplasty can be performed entirely awake in the office, guided by transnasal flexible laryngoscopy, or under general anesthesia with direct microlaryngoscopy. Whichever route is chosen, the goal is the same: guide a fine needle precisely into the paraglottic space lateral to the free edge of the paralyzed fold, without violating the airway lumen or injuring adjacent vessels.
Several needle trajectories reach the same target plane:
• Transcutaneous via the cricothyroid membrane — needle enters below the fold and angles up and laterally ("infra-membranous" approach), useful for awake in-office injection • Transcutaneous via the thyrohyoid membrane — needle enters above the thyroid cartilage and angles down toward the fold • Transcartilaginous — needle passed directly through the thyroid cartilage lamina, useful in older, more ossified cartilage that offers a stable path • Transoral (peroral) — a curved injection needle is passed through the mouth under indirect mirror or flexible endoscopic view while the patient is seated upright and awake • Transnasal working-channel — a channeled flexible laryngoscope allows the needle to be passed down the same scope providing direct visualization, popular for in-office practice
The transcutaneous cricothyroid approach and the channeled transnasal approach are the most widely used for awake, office-based injection, since they let the surgeon watch the fold in real time throughout the injection.
In-office injection under topical (and sometimes local infiltrative) anesthesia has become the dominant approach for hyaluronic acid and calcium hydroxylapatite injections. Topical lidocaine is applied to the nasal passage and larynx, the flexible scope is passed transnasally, and the needle is advanced percutaneously or through the scope’s working channel while the patient breathes and phonates on command — allowing the surgeon to titrate filler to the exact voice result desired.
General anesthesia with direct microlaryngoscopy is reserved for autologous fat injection (which requires a separate fat harvest and typically a larger-bore cannula), for patients who cannot tolerate an awake procedure, or when very precise visualization under the operating microscope is preferred. The trade-off is that the patient cannot phonate under general anesthesia, so the surgeon must estimate the correction rather than watch it happen live.
Awake, in-office injection is completed successfully without conversion to the operating room in roughly 9 of 10 appropriately selected patients — reflecting good tolerability of topical anesthesia and the efficiency of channeled flexible laryngoscopes.
The needle tip must stay lateral to the free vibratory edge of the fold and within the paraglottic plane — injection that is too superficial or too medial can scar the vibratory mucosa and worsen voice quality, while injection that is too deep risks the airway lumen or cartilage. The superior laryngeal artery and vein run near the thyrohyoid membrane and cricothyroid space, so trajectory planning avoids these vessels.
Continuous endoscopic visualization (transnasal scope) lets the surgeon confirm needle tip position by watching for a subtle bulge form under the mucosa at the moment of injection, well before any visible fold displacement — the first, most reliable sign of correct paraglottic placement.
With the needle confirmed in the paraglottic space, filler is delivered in small increments while the awake patient phonates sustained vowels on command. The surgeon watches the treated fold bulge medially in real time through the scope, stopping once the free edge meets its mobile partner and the voice quality audibly improves.
Filler is injected in small aliquots — typically 0.1 to 0.2 mL per pass — rather than as a single bolus, because the paraglottic space expands as material accumulates and small increments avoid overcorrection. Total volume required correlates roughly with the size of the pre-treatment glottic gap and the depth of the paraglottic space, most commonly landing between 0.3 and 1.0 mL per fold.
Because every filler undergoes some early resorption or fluid equilibration over the following days to weeks, surgeons typically aim to overcorrect by roughly 10–20% at the time of injection — leaving the fold looking slightly over-medialized immediately afterward, with the expectation that it will settle to the ideal position within one to two weeks.
The single greatest advantage of awake injection is the immediate feedback loop: the patient sustains an "eee" or counts aloud between aliquots, and the surgeon listens for reduced breathiness and increased loudness while simultaneously watching the glottic gap narrow on the endoscopic display. This allows real-time, patient-specific titration that is simply not possible under general anesthesia, where the endpoint must be estimated from fold appearance alone.
Injection stops once the mobile fold and the augmented fold appose fully at midline during phonation, voice quality subjectively normalizes to the surgeon and patient’s satisfaction, and no further gap is visible on the endoscopic view.
Correctly placed filler spreads within the paraglottic fibrofatty tissue and along the lateral surface of the thyroarytenoid muscle, forming a bulge that pushes the entire membranous fold medially rather than creating an isolated lump. Longitudinal placement along the mid-to-posterior membranous fold — the area of greatest gap in typical paramedian paralysis — is emphasized over the anterior third, where the fold is already well apposed at the anterior commissure.
Overinjection is a recognized complication: too much filler can create a stiff, mass-like segment that impairs the mucosal wave and paradoxically worsens voice quality even as the glottic gap closes — reinforcing why live phonation feedback during injection is so valuable.
When the augmented paralyzed fold meets its mobile counterpart at the midline, glottic closure during phonation is restored: the vibratory source becomes more periodic, subglottic air pressure is regained, and the voice signal changes from breathy and weak to clear and adequately loud. Just as importantly, a competent glottis during swallow substantially reduces the risk of aspiration.
Successful medialization converts an incompetent glottis (breathy, aperiodic, low-intensity voice, often graded G2–G3 on the GRBAS scale before treatment) into a competent one, typically improving to G0–G1. Objective measures — maximum phonation time, jitter, shimmer, and the Voice Handicap Index (VHI-10) — improve significantly within days of injection as the mucosal edges regain the ability to make full contact and build up subglottic pressure during the closed phase of each vibratory cycle.
Because hyaluronic acid and calcium hydroxylapatite gradually resorb, voice benefit is not permanent; most patients experience a slow decline in voice quality over months as filler volume is lost, tracking the material’s expected duration.
A competent glottis is as important for airway protection as it is for voice. During swallowing, rapid, complete vocal fold adduction is one of several laryngeal mechanisms (along with epiglottic inversion and laryngeal elevation) that prevent food and liquid from entering the trachea. In UVFP, the persistent gap allows thin liquids in particular to penetrate below the fold level, risking aspiration pneumonia — especially in older or medically frail patients.
By closing the glottic gap, injection laryngoplasty measurably reduces penetration-aspiration scores on videofluoroscopic or fiberoptic endoscopic swallow evaluation, often allowing patients who required a modified or restricted diet to return to a regular one.
Injection effect wanes as the chosen filler resorbs — hyaluronic acid typically over 3 to 6 months, calcium hydroxylapatite over 12 to 18 months, autologous fat unpredictably but sometimes for years. Patients whose RLN paralysis proves permanent, and who wish to avoid repeat injections indefinitely, are excellent candidates for Type I medialization thyroplasty or arytenoid adduction, which reposition the fold with a permanent implant or suture rather than a resorbable filler.
Because the initial injection so closely mimics the voice result of framework surgery, it doubles as a low-risk predictive trial: patients who respond well to injection can be counseled with confidence that permanent surgery is likely to produce a comparable, more durable benefit.
In-office injection laryngoplasty under flexible endoscopic guidance has transformed the management of glottic insufficiency over the past two decades, shifting a procedure once reserved for the operating room into a routine, well-tolerated office visit. Ongoing refinements include ultrasound-assisted needle guidance, longer-acting biocompatible fillers, and combination approaches pairing early temporary injection with staged laryngeal reinnervation surgery (e.g., ansa cervicalis-to-RLN nerve transfer) to restore active, rather than passive, fold tone in select patients.
Injection laryngoplasty exemplifies a broader shift in laryngology toward staged, reversible interventions: a temporary filler buys time for possible nerve recovery, informs surgical decision-making, and can be repeated indefinitely — or handed off to permanent thyroplasty — based on how the patient actually responds.